Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
ETON Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Eton Pharmaceuticals, Inc.NASDAQ: ETON
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables dips below year-ago levels
Q1 FY2026 accounts receivables of $1.65M (cash outflow) fell 85.0% year over year, behind the +122.4% change in trailing-twelve-month accounts receivables.
Context
- Accounts receivables amounted to 8.0% of revenue in FY2025, unchanged from a year earlier.
- Accounts receivables increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -85.0% toward the trailing-twelve-month pace of +122.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (6.4M) USD
- Year-over-year change
- -105.1%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (6.4M) | -105.1% |
| FY2024 | 2024-12-31 | (3.12M) | -100.0% |
| FY2023 | 2023-12-31 | (1.56M) | -143.1% |
| FY2022 | 2022-12-31 | 3.62M | +166.7% |
| FY2021 | 2021-12-31 | (5.42M) | — |
Accounts Receivables vs competitors
How ETON compares with its peers on the latest reported figures
- ETON's LTM Mar 2026 accounts receivables of $2.99M is the 6th largest of the 10 companies compared; the peer median is $9.33M.
- Its year-over-year change of +122.4% is the 2nd highest of 9, against a peer median of -57.9%.
- Accounts receivables amounts to 3.4% of revenue for ETON, versus a peer median of 3.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $63.73M | -14.2% | -10.4% | 6.6% | |
| LTM Mar 2026 | $22.06M | -1708.0% | +37.0% | 3.3% | |
| LTM Sep 2026 | $13.84M | -76.0% | +168.7% | 2.1% | |
| LTM Mar 2026 | $13.18M | +49.0% | — | 3.6% | |
| LTM Mar 2026 | $9.33M | +913.2% | — | 13.4% | |
| LTM Mar 2026 | $2.99M | +122.4% | — | 3.4% | |
| LTM Mar 2026 | $2.98M | -39.9% | +20.9% | 2.4% | |
| LTM Mar 2026 | $2.71M | -76.9% | +101.6% | 5.3% | |
| LTM Mar 2026 | $49.73K | -134.1% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding ETON) | $9.33M | -57.9% | +37.0% | 3.6% | |
Competitors are the stored peer set for ETON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (1.96M) | (9.02M) | (936K) | (3.82M) | (4.6M) |
| Depreciation & Amortization | 462K | 1.77M | 901K | 1.15M | 4.04M |
| Deferred Income Tax | (546K) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.38M | 4.22M | 3.14M | 3.17M | 5.51M |
| Change in Working Capital | (6.21M) | 7.66M | 3.53M | (698K) | (859K) |
| Accounts Receivables | (5.42M) | 3.62M | (1.56M) | (3.12M) | (6.4M) |
| Inventory | 692K | (7K) | (354K) | (1.31M) | (5.88M) |
| Accounts Payables | (570K) | (8K) | 53K | 2.32M | 6.81M |
| Other Working Capital | (910K) | 4.06M | 5.39M | 1.41M | 4.61M |
| Other Non-Cash Items | 148K | 189K | 184K | 1.18M | 6.43M |
| Operating Cash Flow | (4.72M) | 4.82M | 6.82M | 969K | 10.52M |
| Capital Expenditures | (3.26M) | (2.79M) | (775K) | (26K) | (333K) |
| Acquisitions (Net) | 700K | 0 | 0 | (30M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (2.75M) | 0 | (9.99M) | 0 |
| Investing Cash Flow | (2.56M) | (2.79M) | (775K) | (40.01M) | (333K) |
| Debt Repayment | (150K) | (385K) | (1.16M) | 24.15M | 0 |
| Common Stock Issued | 541K | 0 | 0 | 8.19M | 598K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 251K | 198K | 248K | 217K |
| Financing Cash Flow | 391K | (134K) | (957K) | 32.59M | 815K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.89M) | 1.9M | 5.08M | (6.45M) | 11.01M |
| Free Cash Flow | (7.98M) | 2.03M | 6.04M | 943K | 10.19M |
Eton Pharmaceuticals, Inc.
NASDAQ:ETON
Intrinsic Alpha fair value
Locked
Current Price
$61.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.